Active Pharmaceutical Ingredient (API) Market in India 2024-2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	137 Pages	TechNavio	February, 2024	INF18578071

Best Price Guarantee
Price	from $2,500
Length	137 Pages
Publisher	TechNavio
Published Date	February, 2024
SKU	INF18578071

Active Pharmaceutical Ingredient (API) Market In India 2024-2028

The active pharmaceutical ingredient (API) market in India is forecasted to grow by USD 7.56 bn during 2023-2028, accelerating at a CAGR of 6.49% during the forecast period. The report on the active pharmaceutical ingredient (API) market in India provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by an increasing number of type II drug master files (DMF), a growing emphasis on biosimilar manufacturing, and a growing need to focus on core competencies.

Technavio's active pharmaceutical ingredient (API) market in India is segmented as below:

By Manufacturing Type

Captive APIs
Contract APIs

By Type

Innovative APIs
Generic APIs

By Product Type

Prescription
Over-the-counter (OTC)

This study identifies the paradigm shift in API manufacturing as one of the prime reasons driving the active pharmaceutical ingredient (API) market in India growth during the next few years. Also, increasing patent exercises and adoption of sustainable and environmentally friendly manufacturing practices will lead to sizable demand in the market.

The report on the active pharmaceutical ingredient (API) market in India covers the following areas:

Active pharmaceutical ingredient (API) market in India sizing
Active pharmaceutical ingredient (API) market in India forecast
Active pharmaceutical ingredient (API) market in India industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading active pharmaceutical ingredient (API) market in India vendors that include AbbVie Inc., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., Divis Laboratories Ltd., Dr Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Granules India Ltd., Hetero Labs Ltd., Ind Swift Laboratories Ltd., IOL Chemicals and Pharmaceuticals Ltd., Ipca Laboratories Ltd., JB Chemicals and Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Laurus Labs Ltd., Lupin Ltd., Solara Active Pharma Sciences Ltd., Sun Pharmaceutical Industries Ltd., Suven Pharmaceuticals Ltd., and Torrent Pharmaceuticals Ltd.. Also, the active pharmaceutical ingredient (API) market in India analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

1 Executive Summary: 1.1 Market overview; Exhibit 01: Executive Summary - Chart on Market Overview; Exhibit 02: Executive Summary - Data Table on Market Overview; Exhibit 03: Executive Summary - Chart on Country Market Characteristics; Exhibit 04: Executive Summary - Chart on Market Segmentation by Manufacturing Type; Exhibit 05: Executive Summary - Chart on Market Segmentation by Type; Exhibit 06: Executive Summary - Chart on Market Segmentation by Product Type; Exhibit 07: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Exhibit 08: Parent market; Exhibit 09: Market Characteristics
3 Market Sizing: 3.1 Market definition; Exhibit 10: Offerings of vendors included in the market definition; 3.2 Market segment analysis; Exhibit 11: Market segments; 3.3 Market size 2023; 3.4 Market outlook: Forecast for 2023-2028; Exhibit 12: Chart on India - Market size and forecast 2023-2028 ($ billion); Exhibit 13: Data Table on India - Market size and forecast 2023-2028 ($ billion); Exhibit 14: Chart on India: Year-over-year growth 2023-2028 (%); Exhibit 15: Data Table on India: Year-over-year growth 2023-2028 (%)
4 Historic Market Size: 4.1 Active pharmaceutical ingredient (API) market in India 2018 - 2022; Exhibit 16: Historic Market Size - Data Table on active pharmaceutical ingredient (api) market in India 2018 - 2022 ($ billion); 4.2 Manufacturing Type Segment Analysis 2018 - 2022; Exhibit 17: Historic Market Size - Manufacturing Type Segment 2018 - 2022 ($ billion); 4.3 Type Segment Analysis 2018 - 2022; Exhibit 18: Historic Market Size - Type Segment 2018 - 2022 ($ billion); 4.4 Product Type Segment Analysis 2018 - 2022; Exhibit 19: Historic Market Size - Product Type Segment 2018 - 2022 ($ billion)
5 Five Forces Analysis: 5.1 Five forces summary; Exhibit 20: Five forces analysis - Comparison between 2023 and 2028; 5.2 Bargaining power of buyers; Exhibit 21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; 5.3 Bargaining power of suppliers; Exhibit 22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; 5.4 Threat of new entrants; Exhibit 23: Threat of new entrants - Impact of key factors in 2023 and 2028; 5.5 Threat of substitutes; Exhibit 24: Threat of substitutes - Impact of key factors in 2023 and 2028; 5.6 Threat of rivalry; Exhibit 25: Threat of rivalry - Impact of key factors in 2023 and 2028; 5.7 Market condition; Exhibit 26: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Manufacturing Type: 6.1 Market segments; Exhibit 27: Chart on Manufacturing Type - Market share 2023-2028 (%); Exhibit 28: Data Table on Manufacturing Type - Market share 2023-2028 (%); 6.2 Comparison by Manufacturing Type; Exhibit 29: Chart on Comparison by Manufacturing Type; Exhibit 30: Data Table on Comparison by Manufacturing Type; 6.3 Captive APIs - Market size and forecast 2023-2028; Exhibit 31: Chart on Captive APIs - Market size and forecast 2023-2028 ($ billion); Exhibit 32: Data Table on Captive APIs - Market size and forecast 2023-2028 ($ billion); Exhibit 33: Chart on Captive APIs - Year-over-year growth 2023-2028 (%); Exhibit 34: Data Table on Captive APIs - Year-over-year growth 2023-2028 (%); 6.4 Contract APIs - Market size and forecast 2023-2028; Exhibit 35: Chart on Contract APIs - Market size and forecast 2023-2028 ($ billion); Exhibit 36: Data Table on Contract APIs - Market size and forecast 2023-2028 ($ billion); Exhibit 37: Chart on Contract APIs - Year-over-year growth 2023-2028 (%); Exhibit 38: Data Table on Contract APIs - Year-over-year growth 2023-2028 (%); 6.5 Market opportunity by Manufacturing Type; Exhibit 39: Market opportunity by Manufacturing Type ($ billion); Exhibit 40: Data Table on Market opportunity by Manufacturing Type ($ billion)
7 Market Segmentation by Type: 7.1 Market segments; Exhibit 41: Chart on Type - Market share 2023-2028 (%); Exhibit 42: Data Table on Type - Market share 2023-2028 (%); 7.2 Comparison by Type; Exhibit 43: Chart on Comparison by Type; Exhibit 44: Data Table on Comparison by Type; 7.3 Innovative APIs - Market size and forecast 2023-2028; Exhibit 45: Chart on Innovative APIs - Market size and forecast 2023-2028 ($ billion); Exhibit 46: Data Table on Innovative APIs - Market size and forecast 2023-2028 ($ billion); Exhibit 47: Chart on Innovative APIs - Year-over-year growth 2023-2028 (%); Exhibit 48: Data Table on Innovative APIs - Year-over-year growth 2023-2028 (%); 7.4 Generic APIs - Market size and forecast 2023-2028; Exhibit 49: Chart on Generic APIs - Market size and forecast 2023-2028 ($ billion); Exhibit 50: Data Table on Generic APIs - Market size and forecast 2023-2028 ($ billion); Exhibit 51: Chart on Generic APIs - Year-over-year growth 2023-2028 (%); Exhibit 52: Data Table on Generic APIs - Year-over-year growth 2023-2028 (%); 7.5 Market opportunity by Type; Exhibit 53: Market opportunity by Type ($ billion); Exhibit 54: Data Table on Market opportunity by Type ($ billion)
8 Market Segmentation by Product Type: 8.1 Market segments; Exhibit 55: Chart on Product Type - Market share 2023-2028 (%); Exhibit 56: Data Table on Product Type - Market share 2023-2028 (%); 8.2 Comparison by Product Type; Exhibit 57: Chart on Comparison by Product Type; Exhibit 58: Data Table on Comparison by Product Type; 8.3 Prescription - Market size and forecast 2023-2028; Exhibit 59: Chart on Prescription - Market size and forecast 2023-2028 ($ billion); Exhibit 60: Data Table on Prescription - Market size and forecast 2023-2028 ($ billion); Exhibit 61: Chart on Prescription - Year-over-year growth 2023-2028 (%); Exhibit 62: Data Table on Prescription - Year-over-year growth 2023-2028 (%); 8.4 Over-the-counter (OTC) - Market size and forecast 2023-2028; Exhibit 63: Chart on Over-the-counter (OTC) - Market size and forecast 2023-2028 ($ billion); Exhibit 64: Data Table on Over-the-counter (OTC) - Market size and forecast 2023-2028 ($ billion); Exhibit 65: Chart on Over-the-counter (OTC) - Year-over-year growth 2023-2028 (%); Exhibit 66: Data Table on Over-the-counter (OTC) - Year-over-year growth 2023-2028 (%); 8.5 Market opportunity by Product Type; Exhibit 67: Market opportunity by Product Type ($ billion); Exhibit 68: Data Table on Market opportunity by Product Type ($ billion)
9 Customer Landscape: 9.1 Customer landscape overview; Exhibit 69: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
10 Drivers, Challenges, and Trends: 10.1 Market drivers; 10.2 Market challenges; 10.3 Impact of drivers and challenges; Exhibit 70: Impact of drivers and challenges in 2023 and 2028; 10.4 Market trends
11 Vendor Landscape: 11.1 Overview; 11.2 Vendor landscape; Exhibit 71: Overview on Criticality of inputs and Factors of differentiation; 11.3 Landscape disruption; Exhibit 72: Overview on factors of disruption; 11.4 Industry risks; Exhibit 73: Impact of key risks on business
12 Vendor Analysis: 12.1 Vendors covered; Exhibit 74: Vendors covered; 12.2 Market positioning of vendors; Exhibit 75: Matrix on vendor position and classification; 12.3 AbbVie Inc.; Exhibit 76: AbbVie Inc. - Overview; Exhibit 77: AbbVie Inc. - Product / Service; Exhibit 78: AbbVie Inc. - Key news; Exhibit 79: AbbVie Inc. - Key offerings; 12.4 Aurobindo Pharma Ltd.; Exhibit 80: Aurobindo Pharma Ltd. - Overview; Exhibit 81: Aurobindo Pharma Ltd. - Product / Service; Exhibit 82: Aurobindo Pharma Ltd. - Key offerings; 12.5 Cadila Pharmaceuticals Ltd.; Exhibit 83: Cadila Pharmaceuticals Ltd. - Overview; Exhibit 84: Cadila Pharmaceuticals Ltd. - Product / Service; Exhibit 85: Cadila Pharmaceuticals Ltd. - Key offerings; 12.6 Cipla Ltd.; Exhibit 86: Cipla Ltd. - Overview; Exhibit 87: Cipla Ltd. - Business segments; Exhibit 88: Cipla Ltd. - Key news; Exhibit 89: Cipla Ltd. - Key offerings; Exhibit 90: Cipla Ltd. - Segment focus; 12.7 Divis Laboratories Ltd.; Exhibit 91: Divis Laboratories Ltd. - Overview; Exhibit 92: Divis Laboratories Ltd. - Product / Service; Exhibit 93: Divis Laboratories Ltd. - Key offerings; 12.8 Dr Reddys Laboratories Ltd.; Exhibit 94: Dr Reddys Laboratories Ltd. - Overview; Exhibit 95: Dr Reddys Laboratories Ltd. - Business segments; Exhibit 96: Dr Reddys Laboratories Ltd. - Key offerings; Exhibit 97: Dr Reddys Laboratories Ltd. - Segment focus; 12.9 Glenmark Pharmaceuticals Ltd.; Exhibit 98: Glenmark Pharmaceuticals Ltd. - Overview; Exhibit 99: Glenmark Pharmaceuticals Ltd. - Product / Service; Exhibit 100: Glenmark Pharmaceuticals Ltd. - Key offerings; 12.10 Granules India Ltd.; Exhibit 101: Granules India Ltd. - Overview; Exhibit 102: Granules India Ltd. - Product / Service; Exhibit 103: Granules India Ltd. - Key news; Exhibit 104: Granules India Ltd. - Key offerings; 12.11 IOL Chemicals and Pharmaceuticals Ltd.; Exhibit 105: IOL Chemicals and Pharmaceuticals Ltd. - Overview; Exhibit 106: IOL Chemicals and Pharmaceuticals Ltd. - Business segments; Exhibit 107: IOL Chemicals and Pharmaceuticals Ltd. - Key offerings; Exhibit 108: IOL Chemicals and Pharmaceuticals Ltd. - Segment focus; 12.12 Ipca Laboratories Ltd.; Exhibit 109: Ipca Laboratories Ltd. - Overview; Exhibit 110: Ipca Laboratories Ltd. - Product / Service; Exhibit 111: Ipca Laboratories Ltd. - Key offerings; 12.13 Jubilant Pharmova Ltd.; Exhibit 112: Jubilant Pharmova Ltd. - Overview; Exhibit 113: Jubilant Pharmova Ltd. - Business segments; Exhibit 114: Jubilant Pharmova Ltd. - Key news; Exhibit 115: Jubilant Pharmova Ltd. - Key offerings; Exhibit 116: Jubilant Pharmova Ltd. - Segment focus; 12.14 Laurus Labs Ltd.; Exhibit 117: Laurus Labs Ltd. - Overview; Exhibit 118: Laurus Labs Ltd. - Key offerings; 12.15 Lupin Ltd.; Exhibit 119: Lupin Ltd. - Overview; Exhibit 120: Lupin Ltd. - Product / Service; Exhibit 121: Lupin Ltd. - Key news; Exhibit 122: Lupin Ltd. - Key offerings; 12.16 Sun Pharmaceutical Industries Ltd.; Exhibit 123: Sun Pharmaceutical Industries Ltd. - Overview; Exhibit 124: Sun Pharmaceutical Industries Ltd. - Product / Service; Exhibit 125: Sun Pharmaceutical Industries Ltd. - Key news; Exhibit 126: Sun Pharmaceutical Industries Ltd. - Key offerings; 12.17 Torrent Pharmaceuticals Ltd.; Exhibit 127: Torrent Pharmaceuticals Ltd. - Overview; Exhibit 128: Torrent Pharmaceuticals Ltd. - Business segments; Exhibit 129: Torrent Pharmaceuticals Ltd. - Key offerings; Exhibit 130: Torrent Pharmaceuticals Ltd. - Segment focus
13 Appendix: 13.1 Scope of the report; 13.2 Inclusions and exclusions checklist; Exhibit 131: Inclusions checklist; Exhibit 132: Exclusions checklist; 13.3 Currency conversion rates for US$; Exhibit 133: Currency conversion rates for US$; 13.4 Research methodology; Exhibit 134: Research methodology; Exhibit 135: Validation techniques employed for market sizing; Exhibit 136: Information sources; 13.5 List of abbreviations; Exhibit 137: List of abbreviations
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Country Market Characteristics; Exhibits4: Executive Summary - Chart on Market Segmentation by Manufacturing Type; Exhibits5: Executive Summary - Chart on Market Segmentation by Type; Exhibits6: Executive Summary - Chart on Market Segmentation by Product Type; Exhibits7: Executive Summary - Chart on Vendor Market Positioning; Exhibits8: Parent market; Exhibits9: Market Characteristics; Exhibits10: Offerings of vendors included in the market definition; Exhibits11: Market segments; Exhibits12: Chart on India - Market size and forecast 2023-2028 ($ billion); Exhibits13: Data Table on India - Market size and forecast 2023-2028 ($ billion); Exhibits14: Chart on India: Year-over-year growth 2023-2028 (%); Exhibits15: Data Table on India: Year-over-year growth 2023-2028 (%); Exhibits16: Historic Market Size - Data Table on active pharmaceutical ingredient (api) market in India 2018 - 2022 ($ billion); Exhibits17: Historic Market Size - Manufacturing Type Segment 2018 - 2022 ($ billion); Exhibits18: Historic Market Size - Type Segment 2018 - 2022 ($ billion); Exhibits19: Historic Market Size - Product Type Segment 2018 - 2022 ($ billion); Exhibits20: Five forces analysis - Comparison between 2023 and 2028; Exhibits21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; Exhibits22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; Exhibits23: Threat of new entrants - Impact of key factors in 2023 and 2028; Exhibits24: Threat of substitutes - Impact of key factors in 2023 and 2028; Exhibits25: Threat of rivalry - Impact of key factors in 2023 and 2028; Exhibits26: Chart on Market condition - Five forces 2023 and 2028; Exhibits27: Chart on Manufacturing Type - Market share 2023-2028 (%); Exhibits28: Data Table on Manufacturing Type - Market share 2023-2028 (%); Exhibits29: Chart on Comparison by Manufacturing Type; Exhibits30: Data Table on Comparison by Manufacturing Type; Exhibits31: Chart on Captive APIs - Market size and forecast 2023-2028 ($ billion); Exhibits32: Data Table on Captive APIs - Market size and forecast 2023-2028 ($ billion); Exhibits33: Chart on Captive APIs - Year-over-year growth 2023-2028 (%); Exhibits34: Data Table on Captive APIs - Year-over-year growth 2023-2028 (%); Exhibits35: Chart on Contract APIs - Market size and forecast 2023-2028 ($ billion); Exhibits36: Data Table on Contract APIs - Market size and forecast 2023-2028 ($ billion); Exhibits37: Chart on Contract APIs - Year-over-year growth 2023-2028 (%); Exhibits38: Data Table on Contract APIs - Year-over-year growth 2023-2028 (%); Exhibits39: Market opportunity by Manufacturing Type ($ billion); Exhibits40: Data Table on Market opportunity by Manufacturing Type ($ billion); Exhibits41: Chart on Type - Market share 2023-2028 (%); Exhibits42: Data Table on Type - Market share 2023-2028 (%); Exhibits43: Chart on Comparison by Type; Exhibits44: Data Table on Comparison by Type; Exhibits45: Chart on Innovative APIs - Market size and forecast 2023-2028 ($ billion); Exhibits46: Data Table on Innovative APIs - Market size and forecast 2023-2028 ($ billion); Exhibits47: Chart on Innovative APIs - Year-over-year growth 2023-2028 (%); Exhibits48: Data Table on Innovative APIs - Year-over-year growth 2023-2028 (%); Exhibits49: Chart on Generic APIs - Market size and forecast 2023-2028 ($ billion); Exhibits50: Data Table on Generic APIs - Market size and forecast 2023-2028 ($ billion); Exhibits51: Chart on Generic APIs - Year-over-year growth 2023-2028 (%); Exhibits52: Data Table on Generic APIs - Year-over-year growth 2023-2028 (%); Exhibits53: Market opportunity by Type ($ billion); Exhibits54: Data Table on Market opportunity by Type ($ billion); Exhibits55: Chart on Product Type - Market share 2023-2028 (%); Exhibits56: Data Table on Product Type - Market share 2023-2028 (%); Exhibits57: Chart on Comparison by Product Type; Exhibits58: Data Table on Comparison by Product Type; Exhibits59: Chart on Prescription - Market size and forecast 2023-2028 ($ billion); Exhibits60: Data Table on Prescription - Market size and forecast 2023-2028 ($ billion); Exhibits61: Chart on Prescription - Year-over-year growth 2023-2028 (%); Exhibits62: Data Table on Prescription - Year-over-year growth 2023-2028 (%); Exhibits63: Chart on Over-the-counter (OTC) - Market size and forecast 2023-2028 ($ billion); Exhibits64: Data Table on Over-the-counter (OTC) - Market size and forecast 2023-2028 ($ billion); Exhibits65: Chart on Over-the-counter (OTC) - Year-over-year growth 2023-2028 (%); Exhibits66: Data Table on Over-the-counter (OTC) - Year-over-year growth 2023-2028 (%); Exhibits67: Market opportunity by Product Type ($ billion); Exhibits68: Data Table on Market opportunity by Product Type ($ billion); Exhibits69: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits70: Impact of drivers and challenges in 2023 and 2028; Exhibits71: Overview on Criticality of inputs and Factors of differentiation; Exhibits72: Overview on factors of disruption; Exhibits73: Impact of key risks on business; Exhibits74: Vendors covered; Exhibits75: Matrix on vendor position and classification; Exhibits76: AbbVie Inc. - Overview; Exhibits77: AbbVie Inc. - Product / Service; Exhibits78: AbbVie Inc. - Key news; Exhibits79: AbbVie Inc. - Key offerings; Exhibits80: Aurobindo Pharma Ltd. - Overview; Exhibits81: Aurobindo Pharma Ltd. - Product / Service; Exhibits82: Aurobindo Pharma Ltd. - Key offerings; Exhibits83: Cadila Pharmaceuticals Ltd. - Overview; Exhibits84: Cadila Pharmaceuticals Ltd. - Product / Service; Exhibits85: Cadila Pharmaceuticals Ltd. - Key offerings; Exhibits86: Cipla Ltd. - Overview; Exhibits87: Cipla Ltd. - Business segments; Exhibits88: Cipla Ltd. - Key news; Exhibits89: Cipla Ltd. - Key offerings; Exhibits90: Cipla Ltd. - Segment focus; Exhibits91: Divis Laboratories Ltd. - Overview; Exhibits92: Divis Laboratories Ltd. - Product / Service; Exhibits93: Divis Laboratories Ltd. - Key offerings; Exhibits94: Dr Reddys Laboratories Ltd. - Overview; Exhibits95: Dr Reddys Laboratories Ltd. - Business segments; Exhibits96: Dr Reddys Laboratories Ltd. - Key offerings; Exhibits97: Dr Reddys Laboratories Ltd. - Segment focus; Exhibits98: Glenmark Pharmaceuticals Ltd. - Overview; Exhibits99: Glenmark Pharmaceuticals Ltd. - Product / Service; Exhibits100: Glenmark Pharmaceuticals Ltd. - Key offerings; Exhibits101: Granules India Ltd. - Overview; Exhibits102: Granules India Ltd. - Product / Service; Exhibits103: Granules India Ltd. - Key news; Exhibits104: Granules India Ltd. - Key offerings; Exhibits105: IOL Chemicals and Pharmaceuticals Ltd. - Overview; Exhibits106: IOL Chemicals and Pharmaceuticals Ltd. - Business segments; Exhibits107: IOL Chemicals and Pharmaceuticals Ltd. - Key offerings; Exhibits108: IOL Chemicals and Pharmaceuticals Ltd. - Segment focus; Exhibits109: Ipca Laboratories Ltd. - Overview; Exhibits110: Ipca Laboratories Ltd. - Product / Service; Exhibits111: Ipca Laboratories Ltd. - Key offerings; Exhibits112: Jubilant Pharmova Ltd. - Overview; Exhibits113: Jubilant Pharmova Ltd. - Business segments; Exhibits114: Jubilant Pharmova Ltd. - Key news; Exhibits115: Jubilant Pharmova Ltd. - Key offerings; Exhibits116: Jubilant Pharmova Ltd. - Segment focus; Exhibits117: Laurus Labs Ltd. - Overview; Exhibits118: Laurus Labs Ltd. - Key offerings; Exhibits119: Lupin Ltd. - Overview; Exhibits120: Lupin Ltd. - Product / Service; Exhibits121: Lupin Ltd. - Key news; Exhibits122: Lupin Ltd. - Key offerings; Exhibits123: Sun Pharmaceutical Industries Ltd. - Overview; Exhibits124: Sun Pharmaceutical Industries Ltd. - Product / Service; Exhibits125: Sun Pharmaceutical Industries Ltd. - Key news; Exhibits126: Sun Pharmaceutical Industries Ltd. - Key offerings; Exhibits127: Torrent Pharmaceuticals Ltd. - Overview; Exhibits128: Torrent Pharmaceuticals Ltd. - Business segments; Exhibits129: Torrent Pharmaceuticals Ltd. - Key offerings; Exhibits130: Torrent Pharmaceuticals Ltd. - Segment focus; Exhibits131: Inclusions checklist; Exhibits132: Exclusions checklist; Exhibits133: Currency conversion rates for US$; Exhibits134: Research methodology; Exhibits135: Validation techniques employed for market sizing; Exhibits136: Information sources; Exhibits137: List of abbreviations